Beximco Pharmaceuticals (DHA:BXPHARMA) COGS-to-Revenue : 0.55 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Beximco Pharmaceuticals COGS-to-Revenue?

Beximco Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was BDT6,013 Mil. Its Revenue for the three months ended in Dec. 2023 was BDT10,904 Mil.

Beximco Pharmaceuticals's COGS to Revenue for the three months ended in Dec. 2023 was 0.55.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Beximco Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 was 44.86%.

Beximco Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Beximco Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals COGS-to-Revenue Chart

Beximco Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

COGS-to-Revenue

Get a 7-Day Free Trial

0.53

0.54

0.53

0.54

0.56

Beximco Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.55	0.55	0.56	0.58	0.55

Beximco Pharmaceuticals COGS-to-Revenue Calculation

Beximco Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	21953.29	/	39266.662
	=	0.56

Beximco Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	6012.518	/	10904.211
	=	0.55

Beximco Pharmaceuticals (DHA:BXPHARMA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Beximco Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	6012.518 / 10904.211
	=	44.86 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Beximco Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (DHA:BXPHARMA) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

BXP:UK R2WA:Germany

Address

19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205

Website

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.

Beximco Pharmaceuticals (DHA:BXPHARMA) Headlines

No Headlines